Hardware Podcasts

201 - Inside a $300M FDA Remediation, Lessons from Zimmer to EpiPen Warning Letters, 99.999% Reliability and Quality 4.0

Let's Combinate · 13 Aug 2025 · 34m

AI in practice: 2 real uses of AI described

What this episode covers

Jeff Gensler, a veteran quality executive, details his experience leading massive FDA remediation efforts at Zimmer Biomet and Pfizer’s Meridian Medical Technologies. He explains how his team managed a $300M remediation of 1,400 Design History Files (DHFs) at Zimmer and achieved 99.999% reliability for the EpiPen through rigorous CAPA processes and FDA negotiations. Gensler also discusses his transition to Kindeva Drug Delivery, where he oversaw a state-of-the-art facility buildout, and his current work founding the Quality 4.0 Consortium to help small and mid-sized pharma companies adopt digital quality systems like Electronic Batch Records (EBRs) and AI.

AI in practice

Where this conversation describes AI being used to build or deliver a product. Part of the AI in practice tracker.

ManufacturingAI (specifically 'golden batch' capability)

The speaker describes using AI to analyze end-to-end process data to identify driving features, allowing the company to control those features and predict when processes might go out of spec before defects occur.

“There's a new capability through AI called golden batch where you're able to look across your process end to end, understand what truly is the driving features within your process. And if you can control those driving features, then you can make sure and improve the possibility of producing a good batch every single time.”

Jeff Gensler · Hear it at 29:43

ManufacturingElectronic Batch Records (EBR)30 to 40% reduction in investigations; review time from days to hours

The speaker explains that implementing EBRs allows for real-time machine data integration and hard stops for calibration or training issues, which eliminates documentation errors and reduces the time required for batch record review from days to hours.

“A 30 to 40% reduction investigations just by eliminating documentation errors in loan. The improvements you get for a review of a batch record, rather than having hours and hours of manual review of a paper batch record, 100s of 1000s of items. You can do it real time and review by exception. So, you can do it instead of days. It's hours and minutes.”

Jeff Gensler · Hear it at 33:00

Most relevant to

large enterprises

Topics

Mentioned

Companies
Zimmer Biomet, Pfizer, Meridian Medical Technologies, Kindeva Drug Delivery, 3M
Products
EpiPen
Also
Quality 4.0 Consortium, ISPE, FDA, CDRH

Related episodes from other shows

Other shows on the same ground, closest first.

  • Global Medical Device Podcast · 33m

    #474: Behind the QMSR Audits: The Top 5 FDA Citations & Risk Management Pitfalls

    Nikhil Mangale, Vice President of Quality at Kapstone Medical, discusses the real-world impact of the FDA's Quality Management System Regulation (QMSR) based on seven months of inspection data. He identifies the top five FDA citations as risk management, supplier controls, complaint handling, Unique Device Identification (UDI), and corrective actions, noting that inspectors now focus on operational processes rather than terminology updates like renaming Design History Files (DHF) to Design and Development Files (DDF). Mangale advises companies to implement a three-layer mapping strategy, prioritize risk management as a living process, and maintain open DDFs throughout the product lifecycle to avoid citations. He also clarifies that ISO 13485 certification does not exempt companies from FDA inspections and highlights the continued value of MDSAP enrollment for sites in multiple jurisdictions.

    Certification & complianceQuality & yield
    9 chapters

  • Global Medical Device Podcast · 19m

    #438: QMSR Mythbusters Episode

    Host Etia Nichols from Greenlight Guru explains the FDA's new Quality Management System Regulation (QMSR), which replaces 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, with a mandatory enforcement date of February 2, 2026. Nichols debunks the myth that the Device Master Record (DMR), Design History File (DHF), and Device History Record (DHR) are being eliminated, clarifying they are mapped to the Medical Device File (MDF), Design and Development File (DDP), and Batch or Lot Record respectively. She highlights three critical shifts: the explicit integration of lifecycle risk management as the 'DNA' of the QMS, the loss of audit privilege making internal records inspectable, and retained US-specific requirements like UDI in complaint records and extended record retention.

    Certification & complianceQuality & yield
    1 chapters

  • Global Medical Device Podcast · 30m

    What are the Top Compliance Issues Plaguing Medical Device Manufacturers?

    Tom Rynkiewicz, VP of RA/QA at Raland Compliance Partners, joins host John Spear to discuss the top compliance issues plaguing medical device manufacturers, specifically CAPA, complaints, and design controls. Rynkiewicz argues that these recurring FDA observations stem from flawed internal audit practices that audit isolated quality system components rather than the entire system holistically. He highlights how human behavior and corporate KPIs, such as tracking CAPA turnaround times instead of effectiveness, prevent companies from achieving a true quality culture with zero complaints. The conversation emphasizes the need for system-level auditing and transparency to prepare for potential FDA shifts toward stricter Good Manufacturing Practices (GMP) inspections.

    Quality & yieldCertification & compliance
    7 chapters

  • Global Medical Device Podcast · 51m

    Does Your CAPA Process Need a CAPA?

    Mike Drues, president of Vascular Sciences, joins host Jon Speer of Greenlight Guru to discuss why Corrective and Preventive Actions (CAPA) remain the number one reason for FDA 483 observations and warning letters. They analyze specific regulatory citations, such as failure to initiate CAPAs for systemic complaints and lack of documentation for non-initiation, to highlight common quality management system failures. Drues argues that companies must move beyond rigid metrics like closure time and instead test their CAPA efficacy through proactive 'fire drills' to ensure robust root cause analysis and prevention.

    Quality & yieldCertification & compliance
    8 chapters

  • Global Medical Device Podcast · 26m

    #431: Meet Alex Naber: Insider Insights on Quality Systems, Design Quality, and MedTech's Patient-First Ethos

    Alex Naber, a medical device consultant at Greenlight Guru, discusses his career path from bioengineering to design quality and post-market management at Zimmer Biomet. He explains how Greenlight Guru's eQMS and EDC solutions eliminate the pain points of fragmented, spreadsheet-based design controls by building true, linked traceability directly into the system. Naber also highlights the value of pre-built QMS templates that accelerate implementation for small-to-midsize companies, avoiding the 'bloated' procedures typical of large corporations. Finally, he addresses the upcoming QMSR transition, reassuring listeners that compliance is manageable for those already adhering to ISO 13485.

    Quality & yieldDesign for manufacturing & NPI
    7 chapters

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Let's Combinate. The episode itself belongs to its publisher.